bioRxiv / medRxiv
open access
CC BY-ND 4.0
The HLA-E/NKG2A axis identifies a therapeutic vulnerability in BCG-unresponsive bladder cancer
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Safety and Pharmacology Study of Atezolizumab Alone and in Combination With Bacille Calmette-Guérin (BCG) in High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Participants#451516
- Atezolizumab in Treating Patients With Recurrent BCG-Unresponsive Non-muscle Invasive Bladder Cancer#184863
- Intravesicular Abraxane for Treatment-Refractory Bladder Cancer#912792
- NK Activity Modulation Induced by Intravenous Lidocaine During Colorectal Laparoscopic Surgery#904959
- Metabolism Evaluation Through Resting Indirect Calorimetry in Bladder Cancer (METRICS)#913308
Record · ID 441644
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive